Background 44
disciplines that rely heavily on high-throughput data generation, such as 48 genomics, reducing the impact of false positive and false negative rates in 49 results is a top priority. However, verifying all predictions can be costly and 50 redundant, and testing a subset of findings is often used to estimate the true 51 error profile. To determine how to create subsets of predictions for validation 52 that maximize inference of global error profiles, we developed Valection, a 53 software program that implements multiple strategies for the selection of 54 verification candidates. 55
Results 56
To evaluate these selection strategies, we obtained 261 sets of somatic 57 mutation calls from a single-nucleotide variant caller benchmarking challenge 58 where 21 teams competed on whole-genome sequencing datasets of three 59 computationally-simulated tumours. By using synthetic data, we had complete 60 ground truth of the tumours' mutations and, therefore, we were able to 61 accurately determine how estimates from the selected subset of verification 62 candidates compared to the complete prediction set. We found that selection 63 strategy performance depends on several verification study characteristics. In 64 particular the verification budget of the experiment (i.e. how many candidates -Page 3 of 27-can be selected) is shown to influence estimates. 66
Conclusions 67
The Valection framework is flexible, allowing for the implementation of 68 additional selection algorithms in the future. Its applicability extends to any 69 discipline that relies on experimental verification and will benefit from the 70 optimization of verification candidate selection. 71
Background 72
High-throughput genomics studies often exhibit error profiles that are biased 73 towards certain data characteristics. For example, predictions of single-74 nucleotide variants (SNVs) from DNA sequencing data have error profiles 75 biased by local sequence context [1] [2] , mappability of the region [3] and many 76 other factors [4] [5] . The false positive rate for individual predictions in high-77
throughput studies is frequently high [6] [7] , while the false negative rate is 78 difficult to estimate and rarely known. Critically, error rates can vary 79 significantly between studies because of tissue-specific characteristics, such 80 as DNA quality and sample purity, and differences in data processing 81 pipelines and analytical tools. In cancer studies, variations in normal tissue 82 contamination can further confound genomic and transcriptomic analyses [8-83 10] . 84
Taken together, these factors have necessitated the wide-spread use of 85 studies with orthogonal technologies, both to verify key hits of interest and to 86 quantify the global error rate of specific pipelines. In contrast to a validation 87 study, which typically approaches the same biological question using an 88 independent set of samples (e.g. like a test dataset in a machine learning 89 exercise), we define a verification study as interrogating the same sample-set 90 -Page 4 of 27-with an independent method (i.e. a method that generates analogous data 91 using a distinct chemistry). The underlying concept is that if the second 92 technique has separate error profiles from the first, a comparative analysis 93 can readily identify false positives (e.g. in inconsistent, low quality calls) and 94 even begin to elucidate the false negative rate (e.g. from discordant, high 95 quality calls). 96
The choice of verification platform is critical as it determines both the tissue 97 and financial resources required. There is typically a wide range of potential 98 verification technologies for any given study. While confirmation of DNA-99 sequencing results traditionally involves gold-standard Sanger sequencing 100 [11] [12] , the drawbacks of this approach (e.g. high financial and resource 101 costs) and advancements in newer sequencing techniques have shifted the 102 burden of variant verification to other technologies [13] [14] [15] . For example, a 103 typical Illumina-based next-generation sequencing (NGS) whole-genome or 104 whole-exome experiment may be verified by sequencing a separate library on 105 a different but similar machine [16] . This offers the advantages of high-106 throughput, low cost and the opportunity to interrogate inter-library differences 107 [17] . Other groups have applied mass-spectrometric based corroboration of 108 individual variants, which has the benefit of technological independence [18-109 19] . 110
Apart from choice of technology, all groups must make decisions regarding 111 the scope of their verification work. For example when considering genome-112 wide discovery, it may be appropriate to verify only known candidate drug 113 target mutations or unexpected novel functional aberrations. However, in 114 many contexts having an unbiased estimate of the global error rate is critical. 115 This is particularly true when benchmarking different data-generating methods 116 -Page 5 of 27-or when looking at genome-wide trends. It remains unclear how best to select 117 targets for verification studies, particularly in the context of fairly comparing 118 multiple methods and providing unbiased performance metric estimates. To 119 address this problem, we created Valection, a software tool that implements a 120 series of diverse variable selection strategies, thereby providing the first 121 framework for guiding optimal selection of verification candidates. To 122 benchmark different strategies, we exploit data from the ICGC-TCGA DREAM 123
Somatic Mutation Calling Challenge (SMC-DNA), where we have a total of 124 2,051,714 predictions of somatic SNVs made by 21 teams through 261 125 analyses [20, 4] . We show that the optimal strategy changes in a predictable 126 way based on characteristics of the verification experiments. 127
Results

128
We began by developing six separate strategies for selecting candidates for 129 verification (Figure 1) . The first is a naïve approach that samples each 130 mutation with equal probability, independent of whether a mutation is 131 predicted by multiple algorithms or of how many calls a given algorithm has 132 made ('random rows'). Two simple approaches follow that divide mutations 133 either by recurrence ('equal per overlap') or by which algorithm made the call 134 ('equal per caller'). Finally, we created three approaches that account for both To compare the six methods outlined above, we used data from tumour-145 normal whole-genome sequencing pairs from the ICGC-TCGA DREAM 146
Somatic Mutation Calling Challenge [20, 4] . These tumours differ in major 147 characteristics such as normal contamination, sub-clonality and mutation rate. 148
We chose to work with simulated tumours because we know the ground truth 149 of their mutational profiles, allowing a precise evaluation of the effectiveness 150 of different selection schemes in estimating the true underlying error rates. 151
Altogether, there are results available from 261 SNV calling analyses 152 performed by 21 teams. We designed a rigorous parameter-sweeping 153 strategy, considering different numbers of SNV calling algorithms and different 154 quantities of verification candidate targets. The experimental design is 155 outlined in Figure 2 . 156
We assessed the performance of the candidate-selection strategies in two 157 ways. First, we considered how close the predicted F 1 score from a simulated 158 verification experiment is to that from the overall study. We calculated 159 precision in two modes: 'default' (as described in Methods) and 'weighted' 160 (where precision scores were modified so that unique calls carried more 161 weight than calls predicted by multiple callers). Second, we assessed the 162 variability in this result across 10 replicate runs of each strategy, allowing us 163 to gauge how much random chance elements of variant-selection perturb the 164 results of a given method (i.e. a stability analysis). 165
Overall, across all simulations, the 'equal per caller' approach performs best, 166
showing a negligible mean difference between subset and total F 1 scores 167 while, additionally, displaying low variability (i.e. small spread) in F 1 score 168 -Page 7 of 27-differences across all runs (Figure 3) . Both the number of algorithms tested 169 and the verification budget size (i.e. the number of candidates being selected) 170 factor into which strategy performs optimally. Specifically, when there are 171 large numbers of algorithms or the number of possible verification targets is 172 low, the 'equal per caller' method does extremely well (n targets = 100; 173 Supplementary Figure 1) . By contrast, when the number of verification 174 targets is substantially larger (i.e. a considerable proportion of all predictions 175 will be tested), the 'random rows' method shows similar performance levels 176 (n targets = 1000 and n targets = 2500; Supplementary Figures 2 and 3 , 177 respectively). However, the 'random rows' method performs poorly when 178 prediction set sizes are highly variable (i.e. a small number of callers has a 179 large fraction of the total calls), resulting in some callers with no calls by which 180 to estimate performance. This was the case for runs with verification budgets 181 of n targets = 250 (Supplementary Figure 4) , n targets = 500 (Supplementary 182 Figure 5 ) and, in particular, n targets = 100 (Supplementary Figure 1) . Missing 183 scores were treated as missing data. 184
However, the effects of the verification experiment characteristics described 185 above alone do not account for all the variability observed across the 186 simulations. Comparing runs of matching parameter combinations across the 187 three synthetic tumours reveals some inter-tumour differences. Unlike with 188 tumours IS1 (Supplementary Figure 6 ) and IS2 (Supplementary Figure 7) , 189 the 'random rows' method performs best on tumour IS3 suggesting tumour 190 characteristics may have an impact on target selection strategy performance 191 (Supplementary Figure 8) . The 'equal per caller' method is only the second 192 best selection strategy for the IS3 dataset. with the exception of the 'random rows' method, on which the weighted 199 precision calculation appears to have no effect. A closer look at the recall and 200 precision scores reveals that the approach with the poorest recall score, 201 'decreasing with overlap' (Supplementary Figure 9a) , also shows the most 202 sensitivity to the weighted adjustment step in precision calculations 203 Figure 9b) . Altogether, across methods, recall scores tend 204 to mirror F 1 scores in both magnitude and amount of spread, which is lower in 205 approaches with higher recall. In contrast, precision scores are highly variable 206 across most selection approaches, regardless of their overall performance. independently verify results are substantial, it is vital to choose an unbiased 212 but maximally informative set of results. This is naturally true not just for 213 somatic SNVs, but other predictions like structural variants, fusion proteins, 214 alternative splicing events and epigenetic phenomena, e.g. methylation and 215 histone marks. Ongoing research into the error profiles of various data types 216 increases our understanding of what factors influence verification rates [21] . The need for informative verification target selections also highlights the 235 importance of simulators for experimental biology, since the best suited 236 method may vary from dataset to dataset. Indeed, as our findings here 237 suggest, optimal candidate-selection strategies for somatic SNV calls may 238 even be affected by various tumour data characteristics. A complete 239 assessment of error profiles is impossible without access to multifarious 240 datasets with an established ground truth. As such, there is a need for reliable 241 simulators in biology to create and analyze gold-standard synthetic datasets 242 to help guide top empirical research. For some time computationally-243 simulated data has been used to circumvent the difficulties that arise when 244 working with real data [23] . The production of varied synthetic data is 245 comparatively cheap and efficient, restricted only by the computational power 246 -Page 10 of 27-and storage space required to generate and hold it. With complete control 247 over data feature profiles, researchers are able to query numerous biological 248 questions simultaneously. As demonstrated here, and specific to cancer 249 genomics, synthetic tumour data can expedite accurate estimation of false 250 negative rates which are difficult to determine in genome-wide mutation 251 calling, thus mitigating the need for large-scale wet lab validation of non-252 variants. It is important to note, however, that the utility of synthetic data is 253 limited to non-exploratory research. Biological processes or data features that 254 are unknown or poorly understood cannot be adequately simulated, leading to 255 a lack of 'real-world' complexity. Therefore, the interplay between 256 experimental and simulated data is critical to the advancement of 'big data' 257 disciplines such as genomics. As such, subsequent assessment using 258 comprehensively-characterized real data will be vital to further optimizing 259 candidate-selection strategy. 260
Conclusions 261
Verification of somatic SNV calls made on NGS tumour data is critical due to 262 the high numbers of false positive and false negative calls. However, a 263 thorough search to identify all erroneous calls is a cumbersome and 264 expensive task. Our findings suggest that it may also be an avoidable one. 265
Fewer verification targets may be sufficient to characterize global error rates 266 in data, provided that there is proper optimization of the target candidate 267 selection process. We find that this optimization must factor in not just the 268 scope of the verification study but, conceivably, the characteristics of the 269 dataset itself. To date, few studies have assessed candidate-selection 270 methods for verification purposes. Here, we begin to explore the alternatives 271 available to big data analysts performing confirmatory studies that are both 272 -Page 11 of 27-efficient and thorough. By releasing our Valection software publicly, we 273 encourage groups across the wider research community to continue this work. 274
With a straightforward implementation and easy application, Valection has the 275 potential for maximal impact across a wide range of disciplines that rely on 276 verification studies. 277
Methods
278
Selection Strategies & Software
279
The random rows selection strategy (Figure 1b) samples calls at random 280 without replacement from the entire set of calls, and continues until the 281 verification budget has been reached, or there are no more calls left. 282
The directed-sampling selection strategy (Figure 1c) begins by constructing 283 a matrix. Row 1 contains all the calls made only by individual callers, row 2 284 contains the calls made by exactly 2 callers, all the way to row N, which 285 contains the calls that were made by all of the N callers. Each column, j, of the 286 matrix contains only the calls made the j th caller. Note that this means in all 287 rows past 1, calls appear in multiple cells on the same row. Any given cell 288 holds zero or more calls. To select calls, the following procedure is followed 289 for each row, from N to 1, and for each cell in that row, ordered by ascending 290 number of calls: 291
• Calculate the cell budget as the total remaining verification budget 292 divided among the yet unexamined cells in the rest of the matrix. 293
• Select calls without replacement from the cell in question up to the cell 294 budget (these calls become invalid selections for future cells). Each call 295 selected reduces the total remaining verification budget. 296
• If any budget remains once all cells have been selected from, the 297 -Page 12 of 27-process is repeated. 298
The equal per caller selection strategy (Figure 1d) The equal per overlap selection strategy (Figure 1e) The increasing with overlap selection strategy (Figure 1f ) is similar to equal 314 per overlap, but instead of selecting an equal number of calls at every level of 315 overlap, it selects a number from each level of overlap proportional to the 316 level of overlap. 317
The decreasing with overlap selection strategy (Figure 1g) is identical to 318 increasing with overlap, but the number of calls selected at each level is 319 inversely proportional to the level of overlap. 320
All of these methods are available through four commonly used programming The analysis scripts are also available at http://labs.oicr.on.ca/boutros-332 lab/software/valection. 333
Simulated Data
334
To test the accuracy of these different approaches empirically, we applied 335 them to gold-standard data from the ICGC-TCGA DREAM Somatic Mutation 336
Calling Challenge [20] . This is a global crowd-sourced benchmarking 337 competition aiming to define the optimal methods for the detection of somatic 338 mutations from NGS-based whole-genome sequencing. The challenge has 339 two components, one using simulated data created using BAMSurgeon 340 software [4] and the other using experimentally-verified analyses of primary 341 tumours. To test the accuracy of our approaches on representation 342 algorithms, we exploited the SNV data from the first three in silico tumours. Supplementary Tables 5-7 and a 350 confusion matrix in Supplementary Table 8 . 351
To probe a range of possible verification studies, we ran a very broad set of 352 simulations. For each run, we pre-specified a tumour, a number of algorithms 353 and a number of mutations to be selected for verification, and ran each of the 354 candidate-selection strategies listed above. We then calculated the F 1 score 355 (along with precision and recall) based on the verification study, assuming 356 verification results are ground truth. Finally, we compared the true F 1 for a 357
given algorithm on a given tumour across all mutations to the one inferred 358 from the verification experiment. 359
We used three separate tumours with diverse characteristics 360 (https://www.synapse.org/#!Synapse:syn312572/wiki/62018), including a 361 range of tumour cellularities and the presence or absence of sub-clonal 362 populations. We selected subsets of algorithms for benchmarking in four 363 different ways: 364 i) the complete dataset (X) 365
ii) the single best submission from each team (X-best) 366
iii) three randomly selected entries from X-best (repeated 10 times) 367 iv) 25 randomly selected entries from X (repeated 10 times) 368
Lastly, we considered verification experiment sizes of 100, 250, 500, 1000 369 and 2500 candidates per tumour. Thus, in total, we analyzed each of the 370 candidate-selection algorithms in 22 datasets for 3 tumours and 5 verification 371 sizes, for 330 total comparisons. 372
Statistical Analyses
373
The precision, recall and F 1 score of each caller were calculated as follows, 374 -Page 15 of 27-from the caller's true positive (TP), false positive (FP) and false negative (FN) 375 values, as estimated by the selection strategy. Here, FNs are true calls 376 sampled by the selection strategy that were not made by the caller in question 377 (i.e. another caller made it). 378
(1)
379
(2)
380
(3)
381
When no calls were selected to calculate a value for a caller, scores were 382 given values of N/A. This happened primarily with the 'random rows' method. 383
Additionally, each precision score was calculated in an adjusted and 384 unadjusted manner. A caller's precision in the unadjusted form was calculated 385 exactly as described above, using all the calls made by the caller and 386 selected for verification as the TPs and FPs. In the adjusted form, the 387 selected calls were first divided into groups, according to how many callers 388 made the call. Then, the precision was calculated separately using the calls 389 from each group. The final precision was calculated as a weighted average of 390 the precision of each group of calls, with weights equal to the total number of 391 calls (verified and unverified) that caller made at that overlap level. Thus, in a 392 two-caller example, a caller that made 100 unique calls and 50 calls shared 393 -Page 16 of 27-with the other caller would count its precision from unique calls twice as 394 strongly as its precision from shared calls. 395 Verification candidates were selected from somatic mutation calling results of 485 multiple algorithms run on three in silico tumours (IS1, IS2, and IS3). 486
List of abbreviations
Candidate selection was performed separately on each tumour's set of results 487 using all combinations of five different verification budgets (i.e. number of calls 488 selected) and six different selection strategies. F 1 scores were calculated for 489 each set of selected calls and compared to F 1 scores calculated from the full 490 prediction set. To compare the effect of the numbers of algorithms used, 491 datasets were further subset using four different metrics. 492
Figure 3: All Simulation Results for Selection Strategy Parameter 493
Combinations 494
Overall, the best results are obtained using the 'equal per caller' method. The 495 'random rows' approach scores comparably except in cases where there is 496 high variability in prediction set sizes across callers. Calls from low-call callers 497 are less likely to be sampled at random and, in cases where none are 498 sampled, it is not possible to get performance estimates for those callers. 499
Failed estimate runs are displayed in grey. 500 
